E. Ohman J:or Asset Management’s Cytokinetics CYTK Stock Holding History

E. Ohman J:or Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.9M	Buy	304,611 +3,849	+1%	+$276K	0.6%	44
2026 Q1	$19.8M	Sell	300,762 -62,200	-17%	-$3.95M	0.52%	45
2025 Q4	$23.1M	Sell	362,962 -44,075	-11%	-$2.74M	0.54%	41
2025 Q3	$22.4M	Hold	407,037	–	–	0.53%	43
2025 Q2	$13.4M	Buy	407,037 +77,806	+24%	+$2.71M	0.33%	54
2025 Q1	$13.2M	Buy	+329,231	New	+$15.1M	0.35%	55

Other funds holding CYTK

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

E. Ohman J:or Asset Management's CYTK Position: Q2 2026 in Review

E. Ohman J:or Asset Management increased its Cytokinetics (CYTK) stake by 1.3% in Q2 2026, buying an estimated $276K and bringing the position to 304,611 shares worth $25.9M. The position accounts for 0.6% of the portfolio, ranked #44.

E. Ohman J:or Asset Management first reported a position in CYTK in Q1 2025 and has held it in 6 quarters since. 144 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

E. Ohman J:or Asset Management held 304,611 shares of Cytokinetics worth $25.9M as of Q2 2026.
E. Ohman J:or Asset Management bought 3,849 Cytokinetics shares in Q2 2026, an estimated $276K.
Cytokinetics made up 0.6% of E. Ohman J:or Asset Management's portfolio in Q2 2026, its #44 holding.
E. Ohman J:or Asset Management first reported a position in Cytokinetics in Q1 2025 and has held it in 6 quarters since.
144 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2026, filed 10 Jul 2026.